Tissue Engineering and Biomaterials Laboratory, Fischell Department of Bioengineering, A. James Clark School of Engineering, University of Maryland, College Park, Maryland, USA.
NIBIB/NIH Center of Engineering Complex Tissues, University of Maryland, College Park, Maryland, USA.
Tissue Eng Part B Rev. 2022 Dec;28(6):1223-1234. doi: 10.1089/ten.TEB.2021.0212. Epub 2022 Jul 12.
Accumulation of senescent cells (SnCs) in various tissue types has been connected to an occurrence of different age-related diseases that are indicated by its own tissue-specific hallmarks. Discovery of novel senolytic compounds that target major cellular mechanisms to inhibit the level of SnCs within the specific tissues or organs has been an emerging field in the age-related disease research. Although the positive effect of senolytics in global suppression of SnCs has been well studied in the past, effective tissue-specific delivery strategy of senotherapeutics before clinical application needs to be further investigated. In this review, we discuss the latest biological insights to currently available senotherapeutic options and explore the impactful tissue-engineered models possibly as a testbed for replicable testing of tissue-specific potency of senolytics. Impact statement Senotherapy, the inhibition of accumulated senescent cells, is recognized as a significantly impactful way to treat various human diseases. However, there is limited comprehensive reviews on this topic. This review provides in-depth discussion on diverse delivery strategies of senolytic agents and latest updates on a novel senotherapeutic research.
衰老细胞 (SnC) 在各种组织类型中的积累与不同的与年龄相关的疾病的发生有关，这些疾病具有其自身的组织特异性特征。发现针对主要细胞机制的新型衰老细胞选择性杀伤化合物，以抑制特定组织或器官中衰老细胞的水平，这是与年龄相关的疾病研究中的一个新兴领域。尽管过去已经很好地研究了衰老细胞选择性杀伤化合物在全球抑制衰老细胞方面的积极作用，但在临床应用之前，还需要进一步研究有效的组织特异性衰老治疗药物输送策略。在这篇综述中，我们讨论了当前可用的衰老治疗选择的最新生物学见解，并探讨了有影响力的组织工程模型，作为可复制测试衰老细胞选择性杀伤化合物的组织效力的试验台。 影响评估 衰老细胞抑制疗法，即抑制积累的衰老细胞，被认为是治疗各种人类疾病的一种非常有影响力的方法。然而，关于这个主题的综合评论非常有限。本综述深入讨论了衰老细胞选择性杀伤化合物的多种输送策略，以及衰老治疗研究的最新进展。
